Literature DB >> 6977271

Q fever endocarditis.

M J Tobin, N Cahill, G Gearty, B Maurer, S Blake, K Daly, R Hone.   

Abstract

Despite a worldwide distribution of Coxiella burnetii, only single cases of Q fever endocarditis have been reported outside Great Britain and Australia. We present 10 patients; five were female, only four had a history of environmental exposure, and the mitral valve was involved as commonly as the aortic stenosis, and three patients had a prosthetic valve. We confirm the importance of hepatic involvement, thrombocytopenia and hypergammaglobulinemia as diagnostic features. Diagnosis was established by finding and elevated complement-fixing antibody to Phase I C. burnetii antigen. Tetracycline, with or without lincomycin or cotrimoxazole, was used in nine patients, and one patient received cotrimoxazole as as the sole antibiotic agent. Optimal duration of therapy is unknown. In one patient, relapse followed when treatment was stopped after 18 months. Valve replacement was necessary in five patients, because of hemodynamic problems. Five patients died, and the means survival is 36 months with a range of five to 66 months. We suggest that Q fever endocarditis is frequently missed, and we recommend clinicians to consider the diagnosis in all cases of culture-negative endocarditis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977271     DOI: 10.1016/0002-9343(82)90495-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

1.  Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis.

Authors:  P Y Levy; M Drancourt; J Etienne; J C Auvergnat; J Beytout; J M Sainty; F Goldstein; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

3.  High incidence of Coxiella burnetii markers in a rural population in France.

Authors:  M Thibon; V Villiers; P Souque; A Dautry-Varsat; R Duquesnel; D M Ojcius
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

Review 4.  Diagnosis of Q fever.

Authors:  P E Fournier; T J Marrie; D Raoult
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

5.  A case of Q fever endocarditis treated medically: 9 years of follow-up.

Authors:  D Dalmau; J Castãné; E Alvarez; L Ortega; J Garau
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

6.  Antibiotic susceptibilities of two Coxiella burnetii isolates implicated in distinct clinical syndromes.

Authors:  M R Yeaman; M J Roman; O G Baca
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  Q fever endocarditis: a case report and review of the literature.

Authors:  Marc W Deyell; Brian Chiu; David B Ross; Nanette Alvarez
Journal:  Can J Cardiol       Date:  2006-07       Impact factor: 5.223

8.  Susceptibility of Coxiella burnetii to pefloxacin and ofloxacin in ovo and in persistently infected L929 cells.

Authors:  D Raoult; M R Yeaman; O G Baca
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 9.  Antibiotic treatment of rickettsiosis, recent advances and current concepts.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

Review 10.  Q fever.

Authors:  L G Reimer
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.